| Item Type | Name |
|
Academic Article
|
Epidemiology, molecular mycology, and environmental sources of Fusarium infection in patients with cancer.
|
|
Academic Article
|
Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies.
|
|
Academic Article
|
Fungal sinusitis in the immunocompetent patient: risk factors and surgical management.
|
|
Academic Article
|
Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy.
|
|
Academic Article
|
Invasive aspergillosis in patients with solid tumors.
|
|
Academic Article
|
The safety of interferon-gamma-1b therapy for invasive fungal infections after hematopoietic stem cell transplantation.
|
|
Academic Article
|
Diagnosis of invasive pulmonary aspergillosis using polymerase chain reaction-based detection of aspergillus in BAL.
|
|
Academic Article
|
Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions.
|
|
Academic Article
|
Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
|
|
Academic Article
|
Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy.
|
|
Academic Article
|
Infections in patients with aplastic anemia: experience at a tertiary care cancer center.
|
|
Academic Article
|
Invasive cutaneous fungal infections requiring radical resection in cancer patients undergoing chemotherapy.
|
|
Academic Article
|
Phaeohyphomycosis in a tertiary care cancer center.
|
|
Academic Article
|
International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole.
|
|
Academic Article
|
Posaconazole: a broad-spectrum triazole antifungal.
|
|
Academic Article
|
Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003).
|
|
Academic Article
|
Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study.
|
|
Academic Article
|
Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation.
|
|
Academic Article
|
Trichosporonosis in a tertiary care cancer center: risk factors, changing spectrum and determinants of outcome.
|
|
Academic Article
|
Pentamidine is active in a neutropenic murine model of acute invasive pulmonary fusariosis.
|
|
Academic Article
|
EDTA as an adjunct antifungal agent for invasive pulmonary aspergillosis in a rodent model.
|
|
Academic Article
|
Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions.
|
|
Academic Article
|
Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.
|
|
Concept
|
Mycoses
|
|
Concept
|
Lung Diseases, Fungal
|
|
Academic Article
|
Erratum to Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease [J Antimicrob Chemother 2016; 71
|
|
Academic Article
|
Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease
|
|
Academic Article
|
Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.
|
|
Academic Article
|
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
|
|
Academic Article
|
Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.
|
|
Academic Article
|
Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies.
|
|
Academic Article
|
Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.
|
|
Academic Article
|
Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.
|
|
Concept
|
Invasive Fungal Infections
|
|
Academic Article
|
Real-World Use of Isavuconazole as Primary Therapy for Invasive Fungal Infections in High-Risk Patients with Hematologic Malignancy or Stem Cell Transplant.
|
|
Academic Article
|
Comparing the Real-World Use of Isavuconazole to Other Anti-Fungal Therapy for Invasive Fungal Infections in Patients with and without Underlying Disparities: A Multi-Center Retrospective Study.
|